Factors influencing the activity and fate of benzodiazepines in the body.
1 The clinical pharmacokinetics of the many benzodiazepines used to treat numerous and varied clinical conditions can be influenced by many factors. 2 Combinations of drugs efficacious in the central nervous system can change the onset, intensity and duration of effect as a result of pharmacological, physiological and pharmacokinetic actions. 3 Pharmacokinetic considerations indicate that short to medium long-acting benzodiazepines that depend on only glucuronidation for their major metabolic pathway are the drugs of choice in this category.
D014151:Anti-Anxiety Agents / Q000378:metabolism* / Q000494:pharmacology; D001921:Brain / Q000187:drug effects; D002395:Catecholamines / Q000378:metabolism; D002707:Chlordiazepoxide / Q000378:metabolism; D003975:Diazepam / Q000378:metabolism; D004347:Drug Interactions; D000431:Ethanol / Q000633:toxicity; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D010634:Phenobarbital / Q000494:pharmacology; D011247:Pregnancy; D011485:Protein Binding; D011956:Receptors, Cell Surface / Q000032:analysis; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D014151:Anti-Anxiety Agents; D002395:Catecholamines; D011956:Receptors, Cell Surface; D011963:Receptors, GABA-A; D000431:Ethanol; D005680:gamma-Aminobutyric Acid; D002707:Chlordiazepoxide; D003975:Diazepam; D010634:Phenobarbital